Seeking Alpha

Galena Biopharma (GALE -4.3%) gives a pipeline update at ASCO, saying that NeuVax continues to...

Galena Biopharma (GALE -4.3%) gives a pipeline update at ASCO, saying that NeuVax continues to demonstrate "durable response rates", and that a companion diagnostic for HER2 screening in women with breast cancer "increases accuracy." It also reported positive results from Phase 1/2a studies of its folate binding protein, HLA-A2, a restricted peptide immunotherapy for treating ovarian and endometrial cancer.
Comments (7)
  • captdanger
    , contributor
    Comments (3) | Send Message
     
    This sounds like good news. Why has the stock gone south these past few days?
    3 Jun 2013, 02:37 PM Reply Like
  • tommy1954
    , contributor
    Comments (64) | Send Message
     
    No update on P3 trial of neuvax.
    4 Jun 2013, 02:48 AM Reply Like
  • BaciBiz
    , contributor
    Comments (8) | Send Message
     
    And no update on the P2 trial NeuVax/Herceptin. Although what they did give was good.

     

    /Deaux
    4 Jun 2013, 03:30 AM Reply Like
  • captdanger
    , contributor
    Comments (3) | Send Message
     
    This sounds like good news. Would anyone care to share theories as to why the price has been going south these past few days?
    3 Jun 2013, 02:37 PM Reply Like
  • Jareleft
    , contributor
    Comments (35) | Send Message
     
    rarely have the opportunity to buy
    3 Jun 2013, 02:38 PM Reply Like
  • MichaelJ8
    , contributor
    Comments (579) | Send Message
     
    going down because.... people are taking profits...i think its that simple, probably a good time to buy more before it pounds upward
    4 Jun 2013, 03:36 AM Reply Like
  • listech
    , contributor
    Comments (19) | Send Message
     
    Agree, Michael. Can't see any other reason for drop.
    4 Jun 2013, 10:31 AM Reply Like
DJIA (DIA) S&P 500 (SPY)